Company DescriptionGrifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuumfrom prevention, screening, diagnosis, and prognosis to disease and treatment monitoringto serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.
How the Company Makes MoneyGrifols SA primarily generates revenue through the sale of plasma-derived therapies, which are produced by its Bioscience division. This division is the largest contributor to the company's revenue, driven by the demand for its products in treating conditions such as hemophilia, primary immunodeficiencies, and alpha-1 antitrypsin deficiency. The Diagnostic division provides revenue through the sale of equipment and reagents used in blood testing and transfusion medicine. The Hospital division offers products for hospital pharmacy services, including solutions for intravenous therapy and clinical nutrition. Additionally, Grifols earns money through its Bio Supplies division, which supplies biological products for non-therapeutic use. Strategic partnerships with healthcare providers and research institutions, as well as investments in R&D, also play a vital role in sustaining and growing the company's revenue.